Vault-13

Davern Capital Partners, LP

NY, NY · CIK 2003147 · 13F filing filed 2026-05-14

SEC-registered investment adviser since 2025 · limited partnership

$364.5m reported value +17.9% vs Q4 2025
17positions
80.7%in top 10
4 new 7 added 6 reduced 1 sold out vs Q4 2025

Holdings, Q1 2026

The small lines show how much was held over the last 4 quarters (adjusted for stock splits).

#SecurityTickerShares Value% of portfolioChangeShares change
1 PFIZER INC COM PFE PFE 1,593,942 $44.8m12.28% 12.28% ReducedShares held: Q2 2025 —, Q3 2025 —, Q4 2025 2.0m, Q1 2026 1.6m -448.3k -448,300 -21.9%
2 REGENERON PHARMACEUTICALS COM REGN REGN 44,800 $34.6m9.50% 9.50% ReducedShares held: Q2 2025 —, Q3 2025 —, Q4 2025 52.4k, Q1 2026 44.8k -7.6k -7,620 -14.5%
3 INSMED INC COM PAR $.01 INSM INSM 182,562 $29.9m8.19% 8.19% NewShares held: Q2 2025 —, Q3 2025 —, Q4 2025 0, Q1 2026 182.6k
4 IONIS PHARMACEUTICALS INC COM IONS IONS 386,903 $29.1m7.97% 7.97% AddedShares held: Q2 2025 —, Q3 2025 —, Q4 2025 238.5k, Q1 2026 386.9k +148.4k +148,426 62.2%
5 NATERA INC COM NTRA NTRA 143,966 $28.8m7.90% 7.90% AddedShares held: Q2 2025 —, Q3 2025 —, Q4 2025 78.7k, Q1 2026 144.0k +65.3k +65,316 83.0%
6 BIONTECH SE SPONSORED ADS BNTX BNTX 305,055 $27.1m7.44% 7.44% ReducedShares held: Q2 2025 —, Q3 2025 —, Q4 2025 371.2k, Q1 2026 305.1k -66.2k -66,161 -17.8%
7 ARGENX SE SPONSORED ADR ARGX ARGX 35,045 $25.6m7.02% 7.02% ReducedShares held: Q2 2025 —, Q3 2025 —, Q4 2025 35.7k, Q1 2026 35.0k -640 -640 -1.8%
8 ELI LILLY & CO COM LLY LLY 27,279 $25.1m6.88% 6.88% AddedShares held: Q2 2025 —, Q3 2025 —, Q4 2025 8.3k, Q1 2026 27.3k +19.0k +18,972 228.4%
9 ROYALTY PHARMA PLC SHS CLASS A RPRX RPRX 520,009 $24.9m6.84% 6.84% ReducedShares held: Q2 2025 —, Q3 2025 —, Q4 2025 840.6k, Q1 2026 520.0k -320.6k -320,641 -38.1%
10 ROIVANT SCIENCES LTD SHS ROIV ROIV 873,398 $24.2m6.64% 6.64% ReducedShares held: Q2 2025 —, Q3 2025 —, Q4 2025 1.0m, Q1 2026 873.4k -154.9k -154,900 -15.1%
11 LEGEND BIOTECH CORP SPONSORED ADS LEGN LEGN 1,314,748 $23.8m6.52% 6.52% AddedShares held: Q2 2025 —, Q3 2025 —, Q4 2025 1.1m, Q1 2026 1.3m +258.1k +258,080 24.4%
12 MINERALYS THERAPEUTICS INC COM MLYS MLYS 447,153 $12.1m3.32% 3.32% AddedShares held: Q2 2025 —, Q3 2025 —, Q4 2025 210.6k, Q1 2026 447.2k +236.5k +236,505 112.3%
13 ABIVAX SA SPONSORED ADS ABVX ABVX 78,125 $8.7m2.39% 2.39% AddedShares held: Q2 2025 —, Q3 2025 —, Q4 2025 48.5k, Q1 2026 78.1k +29.6k +29,623 61.1%
14 GENERATE BIOMEDICINES INC COM SHS GENB GENB 591,800 $7.4m2.03% 2.03% NewShares held: Q2 2025 —, Q3 2025 —, Q4 2025 0, Q1 2026 591.8k
15 PROCEPT BIOROBOTICS CORP COM PRCT PRCT 261,200 $6.5m1.79% 1.79% NewShares held: Q2 2025 —, Q3 2025 —, Q4 2025 0, Q1 2026 261.2k
16 STRUCTURE THERAPEUTICS INC SPONSORED ADS GPCR GPCR 126,461 $6.1m1.67% 1.67% NewShares held: Q2 2025 —, Q3 2025 —, Q4 2025 0, Q1 2026 126.5k
17 VIRIDIAN THERAPEUTICS INC COM VRDN VRDN 302,457 $5.9m1.62% 1.62% AddedShares held: Q2 2025 —, Q3 2025 —, Q4 2025 261.6k, Q1 2026 302.5k +40.8k +40,842 15.6%

Sold out since Q4 2025

SecurityTickerShares held beforeValue then
CG ONCOLOGY INC CGON CGON 162,005 $6.7m162.0k shares